Table 1. Characteristics of the immune check inhibitor cases (n=44).
| Characteristics | Classifications | No. (%) |
|---|---|---|
| Sex | Male | 38 (86.4) |
| Female | 6 (13.6) | |
| Age [42−91 (median: 71)] | <60 | 6 (13.6) |
| 60−69 | 13 (29.5) | |
| 70−79 | 19 (43.2) | |
| >80 | 6 (13.6) | |
| Pathology | Squamous cell carcinoma | 29 (65.9) |
| Adenocarcinoma | 13 (29.5) | |
| Unclassified | 2 (4.5) | |
| Line* | 1st | 7 (15.9) |
| 2nd | 18 (40.9) | |
| 3rd | 10 (22.7) | |
| 4th | 5 (11.4) | |
| 5th | 4 (9.1) | |
| 6th | 1 (2.3) | |
| 7th | 1 (2.3) | |
| Frequency of administration [1−25 (median: 4)] | <5 | 29 (65.9) |
| 5−10 | 9 (20.5) | |
| >10 | 6 (13.6) | |
| PS grade (ECOG) | 0 | 12 (27.3) |
| 1 | 20 (45.5) | |
| 2 | 6 (13.6) | |
| 3 | 5 (11.4) | |
| 4 | 1 (2.3) | |
| Smoking history | Smoker | 8 (18.2) |
| Non-smoker | 36 (81.8) | |
| Metastatic sites* | Brain | 9 (20.5) |
| Lung | 20 (45.5) | |
| Liver | 4 (9.1) | |
| Bone | 9 (20.5) | |
| Adrenal grand | 12 (27.3) | |
| Pleural dissemination | 2 (4.5) | |
| Lymph nodes | 16 (36.4) |
*, overlapped cases were included. PS, performance status; ECOG, Eastern Cooperative Oncology Group.